Intensity Therapeutics, Inc. Common stock (INTS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.17M
Last updated: Nov 17, 2026 at 11:04 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 12.6% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 41.5, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about INTS
News
INTS Valuation
- P/B
- 1.3x
INTS Profitability: Margins, ROIC and FCF
Intensity Therapeutics, Inc. Common stock (INTS) has an operating margin of 0.0% and a net margin of 0.0%.
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROE
- -161.8%
Intensity Therapeutics, Inc. Common stock Competitors
The companies most similar to Intensity Therapeutics, Inc. Common stock (INTS) include Marker Therapeutics, Tempest Therapeutics and Tscan Therapeutics.
Sector: Healthcare
Companies most similar to Intensity Therapeutics, Inc. Common stockINTS Analyst Ratings
Intensity Therapeutics, Inc. Common stock (INTS) has a Buy consensus from 6 analysts: 6 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 6
- Strong Buy
- 0
- Buy
- 6
- Hold
- 0
- Sell
- 0
- Strong Sell
- 0
INTS Bull Case vs Bear Case
Bull case
- 100.0% of INTS's analyst ratings are Buy or Strong Buy.
Bear case
- INTS beat EPS estimates in 37.5% of its last 8 reported quarters.
INTS Earnings: Beat Rate and Next Report
Intensity Therapeutics, Inc. Common stock (INTS) beat the EPS estimate in 3 of the last 8 quarters (37.5%).
- Beat rate
- 3 of 8 quarters (37.5%)
- Average surprise
- -65.0%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.77
INTS Earnings Call
The latest INTS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptUpdated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About INTS
Does INTS pay dividends?
Intensity Therapeutics, Inc. Common stock (INTS) does not currently pay a regular dividend.
What is INTS's market cap?
Intensity Therapeutics, Inc. Common stock (INTS) has a market capitalization of $10.17M with a current stock price of $3.07.
INTS pages: Overview, Earnings, Forecast, Financials, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.